Journal of Surgical Research

Vergent Bioscience Initiates Phase 2, Multi-Center VISUALIZE Study Evaluating Efficacy of Tumor-targeted Fluorescent Imaging Agent VGT-309 in Lung Cancer Surgeries

Retrieved on: 
onsdag, december 13, 2023
Technology, Surgery, Clinical Trials, Health Technology, Biotechnology, Health, Robotics, Pharmaceutical, Oncology, Lung, Safety, Pathology, Surgeon, Clinical trial, Patient, Journal of Surgical Research, Lymph, Neoplasm, Conference, University, Cancer, Lung cancer, WCLC, Medical imaging, Dentistry

Vergent Bioscience , a clinical-stage biotechnology company developing tumor-targeted imaging agents, announced that the company has enrolled the first patients in a Phase 2, multi-center study evaluating the efficacy and safety of VGT-309 in patients with cancer in the lung.

Key Points: 
  • Vergent Bioscience , a clinical-stage biotechnology company developing tumor-targeted imaging agents, announced that the company has enrolled the first patients in a Phase 2, multi-center study evaluating the efficacy and safety of VGT-309 in patients with cancer in the lung.
  • The international VISUALIZE study will assess the potential of Vergent’s tumor-targeted fluorescent imaging agent to improve the visibility of difficult-to-find and previously undetected tumors during minimally invasive and robotic-assisted surgical procedures, and reduce the possibility that cancer is left behind.
  • Investigators at six clinical trial sites in the United States and Australia plan to enroll 100 patients.
  • “We look forward to expanding on our previous studies to further evaluate this agent and its ability to facilitate the complete removal of tumor during surgery.”

Virpax Pharmaceuticals Reports 2023 Third Quarter Results and Recent Developments

Retrieved on: 
onsdag, november 15, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, CNS, CRADA, Brain, Research, Chronic pain, Food, Bupivacaine, Post-traumatic stress disorder, Osteoarthritis, US Foods, IND, Nose, Pain management, NCATS, Journal of Surgical Research, FDA, Marketing, Investigational New Drug, NIH, Trauma, MET, Pain, Patent, Central nervous system, Bangladesh Technical Education Board, OTC, Diclofenac, Pharmaceutical industry, 3D printing, Cryptocurrency

Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced its financial results for the three months ended September 30, 2023, and other recent developments.

Key Points: 
  • Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced its financial results for the three months ended September 30, 2023, and other recent developments.
  • On September 27, 2023, Virpax announced results for two pre-clinical Probudur™ dose escalation studies.
  • On July 13, 2023, Virpax announced that it had filed a new provisional patent application with the USPTO entitled “Intranasal Delivery” related to its Envelta™ product candidate.
  • As of September 30, 2023, cash and cash equivalents were $12.2 million, compared to $19.0 million as of December 31, 2022.

Virpax Pharmaceuticals Announces Extension of CRADA with the U.S. Army Institute of Surgical Research

Retrieved on: 
torsdag, oktober 12, 2023
Veterans, Infectious Diseases, Military, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Defense, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Central nervous system, Pain management, Journal of Surgical Research, Bupivacaine, Trauma, U.S. Department of Defense Strategy for Operating in Cyberspace, Post-traumatic stress disorder, Walter Reed Army Institute of Research, CRADA, CNS, Research, Pharmaceutical industry

The USASIR is the U.S. Department of Defense’s primary laboratory for developing solutions for trauma and critical care challenges in combat casualties.

Key Points: 
  • The USASIR is the U.S. Department of Defense’s primary laboratory for developing solutions for trauma and critical care challenges in combat casualties.
  • The trial, which was expected to start earlier this year, was slightly delayed due to a change in leadership at USAISR.
  • Probudur is being developed to significantly reduce or eliminate the need for opioids after surgery in approved indications.
  • In pre-clinical trials, Probudur has shown long duration pain control for at least 96 hours.

Allurion Featured at the 2023 International Bariatric Club Oxford University World Congress

Retrieved on: 
måndag, september 18, 2023
Medical Devices, Health, Surgery, Fitness & Nutrition, General Health, Pharmaceutical, Consultant, University of Oxford, IBC, Obesity, Clinic, Safety, Weight loss, Intelligence, Research, Element, Alan Berg (global nutrition advocate), Congress, Patient, Overweight, Diabetes, Paulo, Hospital, Brazilian Health Regulatory Agency, Laboratory, NYSE, Journal of Surgical Research, Medical device

Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced its participation in the 4th International Bariatric Club (IBC) Oxford World Congress, which takes place at Oxford University, September 18-20, 2023.

Key Points: 
  • Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced its participation in the 4th International Bariatric Club (IBC) Oxford World Congress, which takes place at Oxford University, September 18-20, 2023.
  • Brazilian bariatric surgeon Professor Eduardo Grecco’s presentation, ‘The Perfect Intra-gastric Balloon: Combining Safety with Satiety’, will discuss the role the Allurion Balloon—and all the elements of the Allurion Program—can play in safely and effectively delivering weight loss.
  • His clinic has been using the Allurion Balloon to help patients lose weight since it was approved by the Brazilian Health Regulatory Agency ANVISA in 2022.
  • To build further on this theme, the Congress Experts’ Forum Discussion Session is entitled ‘Battle of the Balloons: Endoscopic Vs Swallowable’.

STUDY FINDS VOMARIS BIOELECTRIC TECHNOLOGY SIGNIFICANTLY DECREASED BIOFILM IN BURN PATIENTS

Retrieved on: 
onsdag, mars 15, 2023
Walter Reed Army Institute of Research, TEWL, Microcurrent electrical neuromuscular stimulator, Burns, Bacteria, Burn, Fig, Annals of Surgery, BAMC, Standard of care, Manuscript, Infection, Burn center, SOC, Indiana University, Brooke Army Medical Center, Patient, Death, Effectiveness, Association for the Advancement of Wound Care, Incidence, Control, Doctor of Philosophy, Journal of Surgical Research, Pharmaceutical industry, Vaccine

1) significantly decreased biofilm presence and severity in all burn wound patients (Fig.

Key Points: 
  • 1) significantly decreased biofilm presence and severity in all burn wound patients (Fig.
  • In addition, the Vomaris dressing significantly decreased the incidence of specific opportunistic bacterial pathogen strains in burn patients (Fig.
  • The bioelectric dressing technology is an important new tool for addressing the significant challenge of biofilm infection," commented Dr. Chan.
  • V.Dox Technology offers clinicians and patients an easy-to-use, economical, one-of-a-kind solution to help combat the threat of biofilm infection," said Vomaris President and CEO Michael Nagel.

Virpax Pharmaceuticals to Utilize Dr. Neil K. Singla to Assist in Development of Probudur™

Retrieved on: 
onsdag, januari 18, 2023
FDA, Other Health, Health, Cannabis, Pharmaceutical, Oncology, Other Science, Infectious Diseases, Surgery, Science, Clinical Trials, International Association, Analgesic, CNS, CRADA, Trauma, Walter Reed Army Institute of Research, American Pain Society, Department of Defense Serum Repository, IASP, Conference, Journal of Surgical Research, Central nervous system, Investigational New Drug, Post-traumatic stress disorder, Interest group, IND, Daubert v. Merrell Dow Pharmaceuticals, Inc., Pain management, APS, Physician, Pharmaceutical industry, Anesthesiology

Probudur’s proprietary formulation is intended for immediate onset and has demonstrated sustained pain control for up to 96 hours in animal studies.

Key Points: 
  • Probudur’s proprietary formulation is intended for immediate onset and has demonstrated sustained pain control for up to 96 hours in animal studies.
  • Dr. Neil Singla is board certified in Anesthesiology and the Founder and Chief Scientific Officer of Lotus Clinical Research, a leading analgesic clinical research organization (CRO) with extensive analgesic and pain-related expertise.
  • Dr. Singla has published extensively and is a frequent lecturer for physicians, pharmaceutical companies, and medical research institutes throughout the country.
  • “Virpax is actively moving its programs forward in anticipation of filing Investigational New Drug applications (INDs) and beginning human clinical trials.

Vergent Bioscience Awarded National Cancer Institute Phase 2 Grant to Advance Clinical Development of VGT-309 in Lung Cancer

Retrieved on: 
tisdag, november 29, 2022
Oncology, Health, Surgery, Clinical Trials, Research, Science, Biotechnology, Indocyanine green, NCI, NIR, MIS, ICG, SBIR, University, National Cancer Institute, Stanford University School of Medicine, Patient, Neoplasm, Penn, Cardiothoracic surgery, Small business, Standard of care, Lung cancer, Thorax, Surgeon, Journal of Surgical Research, NIH, Research, Family, Cathepsin, Division, Trial of the century, Safety, Pharmaceutical industry, Medical imaging

Vergent Bioscience , a clinical-stage biotechnology company developing tumor-targeted imaging agents, announced that the National Cancer Institute (NCI) of the National Institutes of Health (NIH) has awarded the company a Small Business Innovation Research (SBIR) grant of nearly $2 million (Award Number R44CA277890).

Key Points: 
  • Vergent Bioscience , a clinical-stage biotechnology company developing tumor-targeted imaging agents, announced that the National Cancer Institute (NCI) of the National Institutes of Health (NIH) has awarded the company a Small Business Innovation Research (SBIR) grant of nearly $2 million (Award Number R44CA277890).
  • The grant will help fund a Phase 2 clinical study evaluating the companys targeted fluorescent imaging agent, VGT-309, for intraoperative imaging of tumors in patients undergoing lung cancer surgery.
  • We are grateful to the NCI for their support and to the team at the University of Pennsylvanias Perelman School of Medicine for conducting this Phase 2 study.
  • The company is first evaluating VGT-309 in lung cancer, with the potential to expand its application to a wide range of solid tumors.

ARA Releases Free BurnCARE Virtual Trainer App on Google Play

Retrieved on: 
måndag, november 28, 2022
IOS, Burn, Burn center, Evans-Haynes Burn Center, Army of the United States, ARA, Unreal Engine, Army, Journal of Surgical Research, Walter Reed Army Institute of Research, Google Play, Hospital

ORLANDO, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Developed by Applied Research Associates, Inc. (ARA), BurnCARE Virtual Trainer is designed to transform how the U.S. Army trains its medics to treat serious burn injuries.

Key Points: 
  • ORLANDO, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Developed by Applied Research Associates, Inc. (ARA), BurnCARE Virtual Trainer is designed to transform how the U.S. Army trains its medics to treat serious burn injuries.
  • BurnCARE Virtual Trainer is now available to the public for free via Google Play, with an iOS release expected soon.
  • The U.S. Army DEVCOM Soldier Center funded BurnCARE Virtual Trainer to develop a visually accurate and easy-to-access burn care medical training app for medics who dont have extensive experience treating burn injuries.
  • To download the free BurnCARE Virtual Trainer, visit https://play.google.com/store/apps/details?id=com.VH.BurncareApp

Study: Spanish-speaking status gives colorectal cancer patients better outcomes at safety-net hospital

Retrieved on: 
fredag, oktober 28, 2022
Linda, Man, University, SNH, MD, Safety, RUHS, LLU, Hospital, Risk, Record, Surgery, Income, III, Colorectal cancer, Cancer, Language, Journal, Patient, UCR, CA, Journal of Surgical Research, LOMA, Research, Population, Knowledge, Competency management system, Riverside University Health System Medical Center, Health insurance, Medical imaging, Medicine, Medical device

LOMA LINDA, Calif., Oct. 27, 2022 /PRNewswire-PRWeb/ -- A recently published study identifies Spanish-speaking status as a protective factor for patients who received colorectal cancer care in a safety-net hospital (SNH) setting. Findings suggest that other SNHs and healthcare settings could include and engage Spanish-speaking patients to improve their care outcomes, authors say.

Key Points: 
  • LOMA LINDA, Calif., Oct. 27, 2022 /PRNewswire-PRWeb/ -- A recently published study identifies Spanish-speaking status as a protective factor for patients who received colorectal cancer care in a safety-net hospital (SNH) setting.
  • Findings suggest that other SNHs and healthcare settings could include and engage Spanish-speaking patients to improve their care outcomes, authors say.
  • These study outcomes depart from prior studies associating Hispanic ethnicity with lower colorectal screening rates and Spanish-speaking status with poorer colorectal cancer outcomes.
  • Caba Molina and researchers reviewed data from colorectal cancer patients who had been seen by the SNH Riverside University Health System's (RUHS) surgical service.

Thubrikar Aortic Valve completes initial CE Mark-enabling TAVI-1 Study

Retrieved on: 
fredag, oktober 21, 2022
Health, Medical Devices, Surgery, Other Health, General Health, Clinical Trials, Cardiology, Calcification, Edwards Lifesciences, Technology, Surgery, KCRI, EOA, Balloon, Mathematical optimization, CE marking, Patient, Journal of Surgical Research, Research, University Medical Center, Biomedical engineering, Textbook, NYU Langone Health, University, TAV, New, Structural heart disease, Company, TAVI, DRS, Principal, TAVR, MDR, Aortic stenosis, Aortic valve, Biomedicine, EU, Competence, South Dakota Board of Regents, Consultant, Medical device, Bara Kodali

Thubrikar Aortic Valve, Inc., announced today that it has completed the initial CE Mark-enabling study using the Optimum Transcatheter Aortic Valve (Optimum TAV) in patients with severe aortic stenosis.

Key Points: 
  • Thubrikar Aortic Valve, Inc., announced today that it has completed the initial CE Mark-enabling study using the Optimum Transcatheter Aortic Valve (Optimum TAV) in patients with severe aortic stenosis.
  • Williams and Kodali report disclosures with Thubrikar Aortic Valve, Inc.
    Thubrikar Aortic Valve, Inc. is a privately held medical device company near Philadelphia, PA, that has developed a next-generation transcatheter aortic valve, the Optimum TAV, and delivery catheter, collectively called the Optimum TAVI System.
  • Optimum TAV was designed after the natural aortic valve using 30 years of research by the Companys Founder, Dr. Mano Thubrikar.
  • He is the author of The Aortic Valve, a leading textbook covering the fundamentals of valve structure and function.